Major new Rice study reveals what Houstonians care about most in 2021

Hou cares

The annual survey revealed that the percentage of Houston-area residents who had a positive view of the local job market dropped slightly. Photo via Getty Images

Few studies gauge the barometric pressure of the Bayou City like the Kinder Houston Area Survey.

Designed to take the temperature of the general population, the study — now in its 40th year — reveals a Houston citizenry optimistic about its personal futures, per the report.

A little about the study before delving in: The report was conducted by the esteemed Stephen Klineberg, founding director of Rice University's Kinder Institute for Urban Research and emeritus professor of sociology; and Robert Bozick, senior research fellow at the Kinder Institute.

This new survey was unveiled at the Kinder Institute's "Lunch-Out" recent virtual event. Interviews of some 1,051 Harris County adults were conducted between January 18 and March 29 by the National Opinion Research Center at the University of Chicago.

The full report is available online.

The No. 1 concern

Public health concerns, while rarely registering in previous surveys, were cited as the biggest problem facing Houstonians this year, according to a press release. Some 25 percent of respondents cited the pandemic or health-related issues.

Others — 20 percent — pointed to the economy as the biggest problem, that's up from 13 percent last year. Only 14 percent cited crime, and traffic dropped to 13 percent, down from 30 percent last year.

Highlighting a national socioeconomic disparity, 58 percent of Blacks and 66 percent of Hispanics said they had to risk exposure to the coronavirus to keep their jobs during the past year, per the report. That's compared to 41 percent of Asians and only 36 percent of whites.

Additionally, the report notes that Blacks and Hispanics were more likely (at 73 percent and 67 percent, respectively) to know someone who was hospitalized with or died as a result of having COVID-19, compared with whites (57 percent) and Asians (40 percent).

Mental health issues have arisen as a serious problem in equal numbers across ethnic communities. More than 50 percent of respondents — in all four groups — reported feeling more stress and experiencing more emotional problems during the past year, compared with 2020.

Jobs and the economy

Though Houston is an opportunity city, the Kinder Survey revealed that the percentage of Houston-area residents who had a positive view of the local job market dropped slightly, to 61 percent this year from 68 percent in 2020.

A mere 21 percent reported their economic situations were getting better, down from 34 percent in 2020. Notably — for the first time in the 40 years — of the survey, more respondents (25 percent) said their financial situations were getting worse than getting better.

Blacks and Hispanics were also more likely than Asians and whites to have experienced a loss of income and to have received help from government programs in the past year.

Race relations, immigration, and inequity

Positive ratings of relations among ethnic groups in the Houston area declined across the board, especially among Blacks. Whites and Hispanics were significantly more likely than in previous years to agree that Blacks are still a long way from having the same opportunities in life as whites.

The number of people who said the criminal justice system is biased against Blacks increased to 54 percent from 32 percent in 2015, when the question was last asked, per a release.

Weather, religion, and politics

Area residents were less likely than in previous surveys to say it's virtually certain the region will experience more severe storms in coming years (59 percent in 2021, compared with 81 percent in 2018 and 2020).

The number of religious Houstonians continues to decline, with more people than ever indicating they are not part of any faith tradition (22 percent today, compared with 8 percent in 2008) and do not consider religion to be an important part of their lives (26 percent, compared with 10 percent in 2008), per the study.

Meanwhile, 45 percent of those surveyed said they felt closer to the Democratic Party this year, while only 25 percent voiced support for the Republican Party.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings